Olympus (OCPNY) Lowered to “Hold” at Zacks Investment Research

Olympus (OTCMKTS:OCPNY) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “OLYMPUS CORPORATION is a Japan-based company. The Company is engaged in the manufacturing and selling of precision machineries and instruments. The businesses of the Company include Imaging System Business, Medical Systems Business, Life Science Business, Information and Communication Business, and Others Business. Olympus has always been a company that makes people’s dreams come true through innovative products. Olympus cameras have always been at the leading edge of innovation. “

Olympus (OTCMKTS OCPNY) opened at $37.69 on Wednesday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.78 and a quick ratio of 1.28. The firm has a market cap of $13,082.24, a PE ratio of 22.86, a price-to-earnings-growth ratio of 2.74 and a beta of 1.09. Olympus has a 12-month low of $33.17 and a 12-month high of $41.87.

ILLEGAL ACTIVITY NOTICE: This report was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://stocknewstimes.com/2017/12/13/olympus-ocpny-lowered-to-hold-at-zacks-investment-research.html.

Olympus Company Profile

Olympus Corporation is engaged in the manufacture and sale of precision machineries and instruments. The Company’s segments include Medical Business, Scientific Solutions Business, Imaging Business and Others. The Company’s Medical Business manufactures and sells medical endoscopes, surgical endoscopes, endotherapy devices and other products.

Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply